Connect your AI

Kura Oncology KURA Commercialization Services — Revenue Remaining Performance Obligation

Other product segments

Development Services In Combination With Other Therapies

$161.7M—

Development Services For Monotherapy

$27M—

Similar metrics at other companies

FCELService — Revenue Remaining Performance Obligation

$155.4M-5.5%

FCELProduct — Revenue Remaining Performance Obligation

$36.1M-63.2%

WYF

WYFIColocation Services — Revenue Remaining Performance Obligation

$920.95M—

BRK.AOther Sales And Service Contracts — Revenue Remaining Performance Obligation

$14.48B+80.9%

IDTNational Retail Solutions — Revenue Remaining Performance Obligation

$25.27M+8.1%

BLKTechnology Services And Subscription Revenue — Revenue Remaining Performance Obligation

$509M+6.0%

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$942.78M+86.2%

Enterprise value$927.97M+95.5%

P/S13.2×+3.9×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's commercialization services — revenue remaining performance obligation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's commercialization services — revenue remaining performance obligation?: Kura Oncology (KURA) reported commercialization services — revenue remaining performance obligation of $275.7M in Q1 2026.
What does commercialization services — revenue remaining performance obligation mean?: Represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. This metric provides visibility into the future revenue backlog expected to be recognized from commercialization service contracts. It is a key indicator of long-term revenue visibility and the health of the commercial pipeline.